New research reveals that patients who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Findings released in a leading health publication demonstrates that while obese people frequently drop substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing these medications should be cognizant of the risk of quick weight regain when the treatment is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The analysis, which reviewed 37 of trials involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
The team point out that individuals who shed pounds through lifestyle changes alone generally see a more gradual creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Experts propose the mode of action of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."
A Chronic Issue?
The NHS suggest the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the treatment should be considered life-long.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the persistent nature of obesity," similar to managing conditions like diabetes.
User Accounts
Individuals who have discontinued the medication report a intense resurgence of cravings.
"I experienced a switch activating and I was suddenly extremely hungry," said an individual.
The struggle is compounded if individuals have not established permanent dietary or behavioural modifications during therapy.
Significant Adoption
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers caution that while the jabs are effective agents for weight loss, they are not a magic cure and long-term success hinges on combined behavioural management.
